Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 5/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31062311 | 0.84 | ENPP2 (0.50) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL16687395 | 0.84 | ENPP2 (0.50) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL3784998 | 0.84 | ENPP2 (0.50) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL16021767 | 0.84 | ENPP2 (0.50) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL28989623 | 0.84 | ENPP2 (0.50) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL23199573 | 0.84 | ENPP2 (0.50) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL18586306 | 0.79 | MGLL (0.48) | ENPP2ACHE | |
| SCHEMBL14186117 | 0.79 | ENPP2 (0.46) | ENPP2ACHEKDM4E | |
| SCHEMBL63159 | 0.78 | ACHE (0.62) | ENPP2ACHECA4CA6CA5A | |
| SCHEMBL30786359 | 0.76 | ENPP2 (0.43) | ENPP2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ENPP2 1920/4885ACHE 295/4885LPL 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.